|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bacci G, Briccoli A, Rocca M, et al:
Neoadjuvant chemotherapy for osteosarcoma of the extremities with
metastases at presentation: recent experience at the Rizzoli
Institute in 57 patients treated with cisplatin, doxorubicin, and a
high dose of methotrexate and ifosfamide. Ann Oncol. 14:1126–1134.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: state of the art. Cancer metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kager L, Zoubek A, Potschger U, et al:
Primary metastatic osteosarcoma: presentation and outcome of
patients treated on neoadjuvant Cooperative Osteosarcoma Study
Group protocols. J Clin Oncol. 21:2011–2018. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang TF, Wang H, Peng AF, et al:
Inhibition of fatty acid synthase suppresses U-2 OS cell invasion
and migration via downregulating the activity of HER2/PI3K/AKT
signaling pathway in vitro. Biochem Biophys Res Commun.
440:229–234. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen HJ, Lin CM, Lee CY, et al: Kaempferol
suppresses cell metastasis via inhibition of the ERK-p38-JNK and
AP-1 signaling pathways in U-2 OS human osteosarcoma cells. Oncol
Rep. 30:925–932. 2013.PubMed/NCBI
|
|
7
|
Zhao Z, Wu MS, Zou C, et al:
Downregulation of MCT1 inhibits tumor growth, metastasis and
enhances chemotherapeutic efficacy in osteosarcoma through
regulation of the NF-kappaB pathway. Cancer Lett. 342:150–158.
2013. View Article : Google Scholar
|
|
8
|
Zhang S, Guo W, Ren TT, Lu XC, Tang GQ and
Zhao FL: Arsenic trioxide inhibits Ewing’s sarcoma cell
invasiveness by targeting p38 (MAPK) and c-Jun N-terminal kinase.
Anticancer Drugs. 23:108–118. 2012. View Article : Google Scholar
|
|
9
|
Liu R, Li X, Gao W, et al: Monoclonal
antibody against cell surface GRP78 as a novel agent in suppressing
PI3K/AKT signaling, tumor growth and metastasis. Clin Cancer Res.
19:6802–6811. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang YH, Dong YY, Wang WM, et al: Vascular
endothelial cells facilitated HCC invasion and metastasis through
the Akt and NF-kappaB pathways induced by paracrine cytokines. J
Exp Clin Cancer Res. 32:512013. View Article : Google Scholar
|
|
11
|
Zito CR, Jilaveanu LB, Anagnostou V, et
al: Multi-level targeting of the phosphatidylinositol-3-kinase
pathway in non-small cell lung cancer cells. PLoS One.
7:e313312012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shukla S, Bhaskaran N, Babcook MA, Fu P,
Maclennan GT and Gupta S: Apigenin inhibits prostate cancer
progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway.
Carcinogenesis. 35:452–460. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li J, Cao B, Zhou S, et al:
Cyproheptadine-induced myeloma cell apoptosis is associated with
inhibition of the PI3K/AKT signaling. Eur J Haematol. 91:514–521.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qin H, Du X, Zhang Y and Wang R:
Platycodin D, a triterpenoid saponin from Platycodon grandiflorum,
induces G2/M arrest and apoptosis in human hepatoma HepG2 cells by
modulating the PI3K/Akt pathway. Tumour Biol. 35:1267–1274. 2014.
View Article : Google Scholar
|
|
15
|
Liu ZL, Mao JH, Peng AF, et al: Inhibition
of fatty acid synthase suppresses osteosarcoma cell invasion and
migration via downregulation of the PI3K/Akt signaling pathway in
vitro. Mol Med Rep. 7:608–612. 2013.
|
|
16
|
Long XH, Zhang GM, Peng AF, Luo QF, Zhang
L, Wen HC, et al: Lapatinib alters the malignant phenotype of
osteosarcoma cells via downregulation of the activity of the
HER2-PI3K/AKT-FASN axis in vitro. Oncol Rep. Epub 2013/11/01.
2013.PubMed/NCBI
|
|
17
|
McKenna RJ, Schwinn CP and Higinbotham NL:
Osteogenic sarcoma in children. CA Cancer J Clin. 16:26–28. 1966.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fraser GM and Aterman K: Osteogenic
Sarcoma in Young Children: A Case Report with Review of Literature.
Can Med Assoc J. 87:74–78. 1962.PubMed/NCBI
|
|
19
|
Pearson D and Steward JK: Malignant
disease in juveniles. Proc R Soc Med. 62:685–688. 1969.PubMed/NCBI
|
|
20
|
Iwamoto Y, Tanaka K, Isu K, et al:
Multiinstitutional phase II study of neoadjuvant chemotherapy for
osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop
Sci. 14:397–404. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meyers PA, Schwartz CL, Krailo M, et al:
Osteosarcoma: a randomized, prospective trial of the addition of
ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and
high-dose methotrexate. J Clin Oncol. 23:2004–2011. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jawad MU, Cheung MC, Clarke J, Koniaris LG
and Scully SP: Osteosarcoma: improvement in survival limited to
high-grade patients only. J Cancer Res Clin Oncol. 137:597–607.
2011. View Article : Google Scholar
|
|
23
|
Ferrari S, Smeland S, Mercuri M, et al:
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose
methotrexate, cisplatin, and doxorubicin for patients with
localized osteosarcoma of the extremity: a joint study by the
Italian and Scandinavian Sarcoma Groups. J Clin Oncol.
23:8845–8852. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Semba S, Itoh N, Ito M, Harada M and
Yamakawa M: The in vitro and in vivo effects of
2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific
inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer
cells. Clin Cancer Res. 8:1957–1963. 2002.PubMed/NCBI
|
|
25
|
Chen Z, Yang L, Liu Y, et al: LY294002 and
Rapamycin promote coxsackievirus-induced cytopathic effect and
apoptosis via inhibition of PI3K/Akt/mTOR signaling pathway. Mol
Cell Biochem. 385:169–177. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu L, Zaloudek C, Mills GB, Gray J and
Jaffe RB: In vivo and in vitro ovarian carcinoma growth inhibition
by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin
Cancer Res. 6:880–886. 2000.PubMed/NCBI
|
|
27
|
Wempe SL, Gamarra-Luques CD and Telleria
CM: Synergistic lethality of mifepristone and LY294002 in ovarian
cancer cells. Cancer Growth Metastasis. 6:1–13. 2013.PubMed/NCBI
|
|
28
|
Liu ZL, Wang G, Peng AF, Luo QF, Zhou Y
and Huang SH: Fatty acid synthase expression in osteosarcoma and
its correlation with pulmonary metastasis. Oncol Lett. 4:878–882.
2012.PubMed/NCBI
|
|
29
|
Porta R, Blancafort A, Casoliva G, et al:
Fatty acid synthase expression is strongly related to menopause in
early-stage breast cancer patients. Menopause. 21:188–191. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tao BB, He H, Shi XH, et al: Up-regulation
of USP2a and FASN in gliomas correlates strongly with glioma grade.
J Clin Neurosci. 20:717–720. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rahman MT, Nakayama K, Ishikawa M, et al:
Fatty acid synthase is a potential therapeutic target in estrogen
receptor-/progesterone receptor-positive endometrioid endometrial
cancer. Oncology. 84:166–173. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu ZL, Wang G, Shu Y, Zou PA, Zhou Y and
Yin QS: Enhanced antitumor activity of epirubicin combined with
cerulenin in osteosarcoma. Mol Med Rep. 5:326–330. 2012.
|
|
33
|
Liu ZL, Zhou Y, Luo QF, et al: Inhibition
of fatty acid synthase supresses osteosarcoma cell invasion and
migration. Indian J Pathol Microbiol. 55:163–169. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yeh CW, Chen WJ, Chiang CT, Lin-Shiau SY
and Lin JK: Suppression of fatty acid synthase in MCF-7 breast
cancer cells by tea and tea polyphenols: a possible mechanism for
their hypolipidemic effects. Pharmacogenomics J. 3:267–276.
2003.PubMed/NCBI
|
|
35
|
Van de Sande T, De Schrijver E, Heyns W,
Verhoeven G and Swinnen JV: Role of the phosphatidylinositol
3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty
acid synthase in LNCaP prostate cancer cells. Cancer Res.
62:642–646. 2002.PubMed/NCBI
|
